Chromadex Corp.

LOS ANGELES--( BUSINESS WIRE )--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference. Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one meetings with investors. Company Webcast The webcasted fireside chat will take place at 1:15 PM ET on Tuesday, October 1, 2024. The webcast can be accessed at https://app.webinar.net/7yrd0odReoK or on the Company's website at chromadex.com. The webcast will also be available for replay following the event. 1x1 Meetings Mr. Fried and Mr. Yu will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg . Further information on the conference is available at https://lythampartners.com/fall2024 . For additional information on ChromaDex, visit www.chromadex.com . About ChromaDex: ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen ® , the number one healthy-aging NAD+ supplement in the United States † . Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com ). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com , to which ChromaDex regularly publishes copies of its press releases, news, and financial information. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

Lupus nephritis is a potentially life-threatening kidney disease manifestation of systemic lupus erythematosus. After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis.In a phase 3 study called REGENCY, a statistically higher proportion of lupus nephritis patients treated with biannual intravenous Gazyva doses and standard autoimmune disease therapy achieved complete renal responses at 76 weeks compared to those treated with standard therapy alone, Genentech reported Thursday. The trial enrolled a total of 271 participants.Lupus nephritis, a kidney disease-related manifestation of the most common lupus type, systemic lupus erythematosus (SLE), has no cure. Up to one-third of patients (currently some 1.7 million worldwide) will develop end-stage kidney disease within ten years, with dialysis and kidney transplants serving as their only available treatment options, according to Genentech. The potentially life-threatening disease primarily affects women, specifically women of color and women who are of “childbearing” age.“Since dialysis or transplants are often required for patients with advanced kidney disease, these findings could represent an important step forward for people living with this devastating disease,” Roche's chief medical officer and head of global development, Levi Garraway, M.D., Ph.D., said in a company release.The drug met certain secondary endpoints that looked at the proportion of patients who achieved complete renal responses with a successful reduction in corticosteroid use, plus proteinuric responses. But it fell short on secondary responses that looked at patients' mean change in estimated glomerular filtration rates, death or renal-related events and overall renal responses. Roche is sharing the data with regulatory agencies with a goal of making the potential new treatment available “as soon as possible,” the company said in its release. Gazyva is also being studied in children and adolescents with lupus nephritis and patients with membranous nephropathy, childhood-onset idiopathic nephrotic syndrome and SLE.The SLE market is currently populated by GSK’s blockbuster Benlysta and AstraZeneca’s newer offering Saphnelo. According to a recent report from Spherix Global Insights, the treatment landscape is poised for evolution with newer biologics angling to get in the field, including Biogen’s litifilimab, AbbVie’s Rinvoq and Bristol Myers Squibb’s Sotyktu. Gazyva works by attaching to CD20, a protein found on certain types of B cells. As lupus nephiritis is a B cell driven disease, targeting the disease-causing cells could protect the kidneys from further damage and potentially slow or prevent progression to end-stage kidney disease, according to Roche.Roche's Genentech and Biogen have a U.S. partnership for the drug, which scored its first approval in 2013 for chronic lymphocytic leukemia. Outside of its Gazyva collab, Biogen is working with UCB on another SLE candidate, dapirolizumab pegol.Biogen and UCB this week reported a successful phase 3 study for that prospect and are now set to begin a second phase 3 trial to support a potential approval.

Spherix Global Insights looked at which biosimilar brands stand to benefit as AbbVie loses access. Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of biosimilar competition, polling doctors about forces shaping the market and their preferred off-patent options.AbbVie reported global Humira sales of $2.8 billion in the second quarter. That represented a 29% drop on an operational basis but meant Humira remained a major product more than one year on from the launch of the first biosimilar in the U.S. Spherix surveyed 313 physicians, split roughly evenly between gastroenterologists, rheumatologists and dermatologists, to understand what is happening.Significantly more gastroenterologists than rheumatologists or dermatologists expressed favorable views of biosimilars, Spherix said. Nearly half of gastroenterologists proactively choose to prescribe biosimilar brands, the survey found, but rheumatologists and dermatologists have largely been driven to off-patent options by “external pressures.” Those pressures have intensified slower than some people expected.One rheumatologist said two years ago they would have predicted Humira would only account for 10% of the market by late 2024. Yet, at the time of the survey in April, the rheumatologist wasn’t seeing that split nor encountering any issues when prescribing Humira. Another physician said they felt about 30% of patients were on biosimilars, with the rest staying on Humira. The second physician also expected biosimilars to penetrate the market faster and to face “this whole tsunami of just lots and lots of work and just the sudden shift.” Yet, so far, the shift has “been odd,” the physician said in April, because “it's not every payer and it hasn't been as awful as I thought it would be.”AbbVie expects to “maintain parity access to biosimilars for a significant majority of patient lives this year,” Jeffrey Stewart, the company’s chief commercial officer, said on an earnings call in July. Asked by an analyst about 2025, Stewart said Humira access “will certainly be lower than this year,” but AbbVie expects to maintain parity access for a “meaningful” portion of patients across all channels.Spherix looked at which biosimilar brands stand to benefit as AbbVie loses access. Gastroenterologists still favor Amgen’s Amjevita, the first Humira biosimilar to launch in the U.S., but are gradually increasing their use of unbranded adalimumab, as sold by Sandoz, Boehringer Ingelheim and Biocon, and Samsung Bioepis and Organon’s Hadlima. Physicians in the other specialties are increasingly using Hadlima, too.Specific biosimilar brand usage depends on what is covered by the patient’s insurance. As well as fighting among themselves, biosimilar manufacturers face competition from AbbVie’s Humira successors Skyrizi and Rinvoq. Stewart said AbbVie saw around 20% of patients move to drugs with other mechanisms, such as Skyrizi and Rinvoq, when they lost access to Humira.